Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.

Calcif Tissue Int · 2016 · PMC4723633 · PMID 26466937

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

Adverse Event The overall adverse event incidence was higher in the DL group compared with the non-DL group with a marginal significance (Table 5 ), but no specific adverse events were related to this increase in the DL group.

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.